RCKT: FDA cleared resumption of Danon trial; strong pipeline and cash runway support growth
The conference highlighted rapid progress in cardiovascular gene therapy programs, with FDA clearance to resume the Danon disease trial, robust patient identification, and strong long-term safety and efficacy data. Updates on PKP2 and BAG3 programs, as well as a Q4 launch for KRESLADI, were also di…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.